Conversely, the overall cancer risk was slightly higher in patients who had taken tofacitinib vs. anti-TNF agents (RR 1.43; 95% CI 1.03–2.04; I2 = 0.00%; p = 0.03) (Supplementary Materials, Figures S1 and S2). This evidence concerns the gene TNF and cancer.